Op deze pagina vindt u het laatste nieuws uit de wereld van klinisch onderzoek! Voor het nieuwsoverzicht (nieuwsfeed) op deze pagina worden van een aantal organisaties, instanties, bedrijven en personen de RSS feeds gevolgd. De RSS feeds worden elke 5 – 10 minuten ververst en op deze pagina weergegeven. Voor een overzicht van alle nieuwsbronnen, klik hier.
Omdat de plug-in die ik voor deze pagina gebruik niet overweg kan met de RSS feeds van een aantal organisaties, instanties, bedrijven en personen heb ik een alternatieve pagina ingericht om de RSS feeds van deze organisaties, instanties, bedrijven en personen toch weer te kunnen geven. Klik hier om het alternatieve nieuwsoverzicht te raadplegen.
Meer nieuws en actualiteiten:
- Alternatief nieuwsoverzicht
- Archief Nieuwsbrief voor Goede Onderzoekspraktijken
- Uitgelicht & Gespot op internet
Nieuwsfeed
- Valproate Information
- FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines
- Sleep Disorder (Sedative-Hypnotic) Drug Information
- April - June 2012 | Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS)
- Acetaminophen
- October - December 2012 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
- FDA issues agency-initiated proposed order regarding OTC monograph drugs containing acetaminophen
- Medication Errors Related to CDER-Regulated Drug Products
- Adenosine Information
- FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
- FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl
- Your Thymus and Your Healthspan
- FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses
- FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone
- FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)
- FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
- FDA Drug Safety Communication: Safety review update of cancer drug Revlimid (lenalidomide) and risk of developing new types of malignancies
- FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment
- FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)
- FDA Drug Safety Communication: Seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine)
- Sildenafil (marketed as Viagra and Revatio) Information
- FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension
- FDA Drug Safety Communication: Rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers
- FDA Drug Safety Communication: Ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure
- FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays
- FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products
- FDA Drug Safety Communication: Important change to heparin container labels to clearly state the total drug strength
- FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events
- FDA Drug Safety Communication: Warning against use of Xyrem (sodium oxybate) with alcohol or drugs causing respiratory depression
- FDA Drug Safety Communication: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin
- FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves
- Weekend reads: How to buy a scientific paper; creating responsible authorship culture; sanction authors for hallucinated references?
- Weekend reads: How to buy a scientific paper; creating responsible authorship culture; sanction authors for hallucinated references?
- Are You Liable? What All Clinical Stage Companies Should Understand About Risk Disclosure
- In a World with Many Epsteins, Does Ethics Still Matter?
- The RW Daily: Former cancer researcher found guilty of attempting to take research to China. And university detects plagiarism in 95% of theses.
- Is Agentic AI The ‘Next Leap Forward’ for Clinical Trial Data Management?
- Old Habits, Communication Issues Still Stalling Site Budget Negotiations
- Untitled Letters Regarding Advertising & Promotional Labeling for Approved Biologics
- Medical Device Accessories - Describing Accessories and Classification Pathways
- eSubmitter Application History
- Herregistratie regelen via MijnRGS eenvoudiger
- [134] Figuring Out Figure 1
- The RW Daily: Technology journal pulls papers for unauthorized author changes, fictitious emails. And "I tried to buy a scientific paper."
- Enabling innovation at temperatures as cold as deep space
- Europese artsen waarschuwen: versoepeling AI-regels bedreigt patiëntveiligheid
- The Art Of Finding And Keeping The Right KOL
- Navigating Ethical Dilemmas in Qualitative Research with Vulnerable Groups in Indonesia
- Implications of COVID-19 Restrictions on the Ethics and Methods of a Multi-Site Study on Alcohol and Other Drug (AOD) Use Treatment among Men in South Africa
- Recently Issued Guidance Documents
